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Increased blood pressure variability (BPV), which can be experimentally induced by
sinoaortic denervation (SAD), has emerged as a new marker of the prognosis of
cardiovascular and renal outcomes. Considering that increased BPV can lead to
organ-damage, the goal of the present study was to evaluate the effects of SAD on renal
function in an experimental model of chronic kidney disease (CKD). SAD was performed
in male Wistar rats 2 weeks before 5/6 nephrectomy and the animals were evaluated 4
weeks after the induction of CKD. Our data demonstrated that BPVwas increased in SAD
and CKD animals and that the combination of both conditions (SAD+CKD) exacerbated
BPV. The baroreflex sensitivity index was diminished in the SAD and CKD groups; this
reduction was more pronounced when SAD and CKD were performed together. 5/6
nephrectomy led to hypertension, which was higher in SAD+CKD animals. Regarding
renal function, the combination of SAD and CKD resulted in reduced renal plasma and
blood flow, increased renal vascular resistance and augmented uraemia when compared
to CKD animals. Glomerular filtration rate and BPV were negatively correlated in SAD,
CKD, and SAD+CKD animals. Moreover, SAD+CKD animals presented a higher level of
glomerulosclerosis when compared to all other groups. Cardiac and renal hypertrophy, as
well as oxidative stress, was also further increased when SAD and CKD were combined.
These results show that SAD prior to 5/6 nephrectomy exacerbates renal dysfunction,
suggesting that previous augmented BPV should be considered as an important factor
to the progression of renal diseases.
Keywords: blood pressure variability, sinoaortic denervation, chronic kidney disease, 5/6 nephrectomy, renal
function
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INTRODUCTION
It is well-established that the maintenance of blood pressure
(BP) at stable levels is a sine qua non condition for adequate
tissue perfusion (Vasquez et al., 2012). Increased blood pressure
variability (BPV) is closely associated with the development,
progression and severity of cardiac, vascular, and renal organ
damage (Sander et al., 2000; Sega et al., 2002; Mancia and Parati,
2003; Tatasciore et al., 2007) as well as with an augmented risk of
cardiovascular and renal outcomes (Kikuya et al., 2000; Pringle
et al., 2003; Hansen et al., 2010; Stolarz-Skrzypek et al., 2010).
Focusing on the kidney, renal function is linearly negatively
associated with BPV, and changes in this parameter, regardless the
mean BP levels, may predict the development and progression of
renal damage (Parati et al., 2012).
Experimentally, increased BPV can be induced by the bilateral
disruption of the afferent pathway of the arterial baroreflex
system (Kudo et al., 2009), also known as sinoaortic denervation
(SAD). This model results in a transient elevation of BP, followed
by its normalization within a few days (Osborn and England,
1990) and increased BPV (Norman et al., 1981). In rats, SAD
also leads to cardiac hypertrophy with impaired diastolic and
systolic function, as well as pulmonary hypertension (Flues et al.,
2012). In the kidney, SAD causes significant alterations in renal
structures, such as patchy focal sclerotic changes associated with
glomerular and tubular atrophy, and interstitial fibrosis in the
renal cortex. The interlobular and afferent arterioles adjacent to
the sclerotic lesions present arteriolar remodeling characterized
by VSMC proliferation and extracellular matrix deposition,
leading to the luminal narrowing and occlusion (Aoki et al.,
2014).
Chronic kidney disease (CKD) is a serious disorder, and
its prevalence is increasing worldwide (James et al., 2010).
The progressive nature of CKD and the ensuing end-stage
renal disease put a substantial burden on global health-care
resources (Meguid El Nahas and Bello, 2005). The classical
mechanisms involved in the progression of CKD include
activation of the renin-angiotensin system, increased oxidative
stress, inflammatory cytokines and deposition of extracellular
matrix, usually due to hypertension and/or diabetes (Pirkle and
Freedman, 2013; Miranda-Díaz et al., 2016). However, increasing
evidence has showed that augmented BPV can also be related
to the clinical outcomes in patients with CKD (Mallamaci
and Tripepi, 2013). Considering that, we hypothesized that
increased BPV prior to the onset of kidney disease could
accelerate the disease progression. To test this hypothesis, we
evaluated the effects of SAD previously to 5/6 nephrectomy-
induced CKD on renal function, glomerulosclerosis, oxidative
stress, and cardiovascular parameters. Our data demonstrate that
augmented BPV prior to CKD exacerbates kidney dysfunction
and should be considered as an important risk factor to the
progression of renal diseases.
MATERIALS AND METHODS
Animals
Experiments were conducted in male Wistar rats (8–10 weeks
old), bred andmaintained in the animal care facility at the Federal
University of Espirito Santo, Brazil. The animals were housed in
individual cages with a controlled temperature (22–23◦C) and
humidity (60%) and exposed to a 12:12-h light-dark cycle. All
of the experimental procedures were performed in accordance
with the National Institutes of Health (NIH) guidelines, and
the experimental protocols were previously approved by the
Institutional Animal Care and Use Committee (CEUA-UFES
Protocol n◦. 03/2012).
Experimental Groups
The animals were randomly divided into 4 groups: control
(Sham), sinoaortic denervated (SAD), 5/6 nephrectomy (CKD)
and SAD+ 5/6 nephrectomy (SAD+CKD).
SAD was performed bilaterally in rats under anesthesia with a
mixture of ketamine (50mg/Kg, ip) and xylazine (10mg/Kg, ip).
After a midline neck incision, sternocleidomastoid muscles were
reflected laterally, exposing the neurovascular sheath. Then, the
aortic fibers traveling along the sympathetic trunk or as isolated
fibers were resected as well as the superior laryngeal nerve. The
superior cervical ganglia were also removed. To complete SAD,
the carotid bifurcation was widely exposed, and the surrounding
connective tissue was stripped off. The carotid fiber and the
carotid body were sectioned (Krieger, 1964; Miao et al., 2006).
The control group underwent a sham operation.
A well-established experimental model of CKD is the 5/6
nephrectomy, which was performed in this study. Two weeks
after the SAD or sham procedure, the animals were anesthetized
with a mixture of ketamine (50mg/Kg, ip) and xylazine
(10mg/Kg, ip). Two of the three ramifications of the left renal
artery were ligated, causing an infarction of ∼2/3 of the renal
mass. The right renal artery and vein were ligated and the right
kidney was removed. After these procedures, the peritoneum and
the skin were sutured.
Haemodynamic Measurements, Baroreflex
Sensitivity Index (BSI) and BPV
Determination
Four weeks after CKD induction, the animals underwent
catheterization procedures. After anesthesia (ketamine 50 mg/Kg
and xylazine 10mg/Kg, ip.), a polyethylene catheter filled with
heparin solution (50UI/mL saline) was inserted into the femoral
artery to measure mean arterial pressure (MAP), systolic blood
pressure (SAP), diastolic blood pressure (DAP) and heart
rate (HR), as well as for blood sampling. The vein was also
catheterized for drug administration. The rats were allowed to
recover during a 24-h period after the catheterization. To record
arterial pressure, the arterial catheter was connected to a pressure
transducer (Cobe Laboratories, USA) plugged into a pressure-
processor amplifier and data acquisition system (MP100, Biopac
Systems, USA). A 45-min recording of MAP, SAP, DAP, and HR
was obtained from conscious and freely moving rats. The BPV
was quantified using the standard deviation of MAP during the
recorded period.
The effectiveness of SAD was confirmed by testing the reflex
heart rate responses to changes in arterial pressure during
intravenous injections of phenylephrine (0.25–32.0µg/kg) and
sodium nitroprusside (0.05–1.6µg/kg), in order to achieve
changes in blood pressure ranging from 5 to 50mmHg. For
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each animal, BSI was calculated using the mean of changes
in HR/mean of changes in MAP elicited by the different
doses of phenylephrine and sodium nitroprusside. BSI for each
group was calculated by averaging the BSI of the all evaluated
animals.
Renal Function Studies
Renal function was determined using inulin (IN) and
sodium para-aminohippurate (PAH) clearance to estimate
the glomerular filtration rate (GFR) and renal plasma flow
(RPF), respectively (Smith et al., 1945). Four weeks after CKD
induction, a separate set of animals were anesthetized with
sodium thiopental (50mg/Kg ip.), the trachea was catheterized
with a polyethylene tube (PE-90) to facilitate breathing, and
a catheter (PE-240) was introduced into the bladder for urine
sampling. The arterial catheter was connected to a pressure
transducer (Cobe Laboratories, USA) plugged into a pressure-
processor amplifier and data acquisition system (MP100, Biopac
Systems, USA) for continuous monitoring of MAP, SAP, DAP,
and HR. The venous catheter was connected to an infusion
pump (0.1mL/min) and a saline solution (0.9%) containing 3%
of mannitol was infused over 30min. After this stabilization
period, the animals received an intravenous injection of prime
solution containing IN (300mg/Kg) and PAH (6.66mg/Kg)
and were maintained on a continuous infusion of saline (0.9%)
containing IN (15mg/mL), PAH (4mg/mL) and mannitol (3%)
until the end of the experiment. At 30-min intervals, urine and
blood samples were taken, for a total of 4 samples. Haematocrit
was measured using a heparinized capillary tube. Plasma and
urinary IN and PAH concentrations were measured using a
colorimetric assay (Rocco et al., 2008). Blood samples were also
used for plasma urea quantification through spectrophotometry.
Renal blood flow (RBF) and renal vascular resistance (RVR)
were determined as previously described (Magalhães et al., 2006).
Briefly, RBF was calculated by the equation RBF = RPF/(1-
haematocrit), and RVR was calculated using the equation
RVR=MAP/RBF.
In order to be able to correlate BPV with renal function,
some animals were submitted to both procedures. For these
animals, BPV was determined as above mentioned and inulin
and PAH clearance was performed in the next day. Due to the
high mortality rate when the two procedures were performed,
especially in the SAD+CKD group, the number of animals in
correlation analysis is limited to 4–6.
Urinary water excretion (24 h) was obtained using a metabolic
cage to avoid the effects of anesthesia and/or mannitol required
to perform renal haemodynamic evaluation. By the end of the
treatment, a separated group of animals were placed onmetabolic
cages during a 24-h accommodation period, followed by urine
sampling also during 24 h.
Quantification of Superoxide Production
Reactive oxygen species generation was performed in blood
cells using flow cytometry. Briefly, blood samples were lysed
with lysing buffer 1X (Becton Dickinson) for 10min at 37◦C
to remove erythrocytes. The cell suspension was then washed
twice in phosphate-buffered saline (PBS) plus 1% Foetal Bovine
Serum (FBS) for 10min and centrifuged at 1200 rpm; and
the supernatant was discarded. The cells were collected and
resuspended in 1mL PBS for flow cytometry analysis. For
intracellular superoxide anion generation measurements, DHE
(160mM) was added to the cell suspension (106 cells), which
was then incubated at 37◦C for 30min in the dark. Samples were
treated with 10mM doxorubicin for 5 min to create oxidative
stress without cell toxicity for the positive control, and the
negative control cells were incubated with ethanol. After washing
and resuspending in PBS, the cells were maintained on ice for
immediate detection by flow cytometry (FACSCanto II, Becton
Dickinson, San Juan, CA, USA). Data were analyzed using
FACSDiva software (Becton Dickinson). For DHE fluorescence
quantification, samples were acquired in duplicate, and 10,000
events were used for each measurement. Red fluorescence
was detected between 564 and 606 nm using a 585/42
bandpass filter. Data are expressed as the median fluorescence
intensity.
Cardiac and Kidney Hypertrophy and
Glomerular Collagen Deposition
At the end of the experiments, the animals were euthanized
with an overdose of sodium thiopental and perfused via the
left ventricle with Krebs-Hepes buffer (pH 7.4). The left kidney
and the heart were removed, cleaned of connective tissue and
weighed. To generate the hypertrophy index, the ratio of kidney
or heart weight to body weight was calculated. Immediately
after being weighed, the kidneys were cut longitudinally, fixed in
Bouin solution and then embedded in paraffin. Five micrometer-
thick sections were obtained and stained with Masson’ trichrome
for glomerular collagen deposition quantification. The glomeruli
were photographed for later analysis. Images were captured
with color video camera (VKC150; Hitachi, Tokyo, Japan)
connected to a microscope (AX70; Olympus, Center Valley,
PA) and analyzed with a specific image program (2100 Leica
EWS; Leica, Wetzlar, Germany) by a person blinded to
the experimental groups. To determine glomerular sclerosis,
at least 30 glomeruli were analyzed in Masson’s trichrome-
stained sections using the Image J program. The mean of the
glomerular-stained areas (%) was used to determine the collagen
deposition for each animal. The glomerulosclerosis index was
determined using a semi-quantitative scale based on % stained
area of the glomerulus: (1) 0–25; (2) 25–50; (3) 50–75; and
(4) >75%.
Statistical Analysis
Values are expressed as means ± S.E.Ms. Statistical comparisons
between the different groups were performed by Student’s t-
test or two-way analysis of variance (ANOVA) followed by
Bonferroni’s post-hoc test. The correlation between BPV and GFR
variables was examined using Pearson’s correlation coefficient.
Statistical significance was assessed using a linear regression
model. The statistical analyses were performed using Prism
software (Prism 5, GraphPad Software, Inc., San Diego, CA,
USA). A value of p< 0.05 was regarded as statistically significant.
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RESULTS
Haemodynamic Measurements, Baroreflex
Sensitivity Index (BSI) and BPV
Determination
Table 1 summarizes the results of systolic (SAP), diastolic (DAP),
and mean (MAP) arterial pressure and heart rate (HR) in
conscious animals 24 h after the catheterization surgery. No
differences were observed in any parameters between sham and
SAD group. On the other hand, CKD animals presented a greater
SAP, DAP, and MAP when compared to the sham and SAD.
Interestingly, these changes were exacerbated in the SAD+CKD
animals, which also displayed an increased HR.
The results of the baroreflex sensitivity index (BSI)
determination are displayed in Figure 1. Figure 1A shows
typical recordings of phenylephrine-induced bradycardic
responses (left) and BSI quantification (right) in all studied
groups. As expected, the BSI was significantly reduced in
the SAD group (−0.45 ± 0.03 bpm/mmHg, p < 0.01) when
compared to the sham animals (−1.7 ± 0.06 bpm/mmHg). CKD
animals also displayed a slightly reduction in BSI (−1.20 ±
0.03 bpm/mmHg, p < 0.01). The combination of SAD and CKD
led to a greater reduction in BSI (−0.22 ± 0.03 bpm/mmHg,
p < 0.01) when compared to all other groups. Figure 1B
shows typical recordings of sodium nitroprusside-induced
tachycardic responses (left) and BSI quantification (right) in all
studied groups. Like in the bradycardic responses, SAD (0.50 ±
0.02 bpm/mmHg, p < 0.01) and CKD (2.00 ± 0.09 bpm/mmHg,
p < 0.01) animals presented a diminished BSI when compared
to the sham group (2.93 ± 0.08 bpm/mmHg). Once again, the
combination of SAD and CKD worsened this parameter (0.26 ±
0.03 bpm/mmHg, p < 0.01).
We also evaluated BP variability using the standard deviation
(SD) of MAP. As demonstrated in Figure 2, the SAD animals
presented an increased SD of MAP (5.53 ± 0.13mmHg,
p < 0.01) when compared to the sham group (2.40 ±
0.05mmHg). CKD also augmented the SD of MAP (3.69 ±
0.12mmHg, p < 0.01); however, when CKD was combined
with SAD, the increase in BP variability was more pronounced
(8.51 ± 0.12mmHg, p < 0.01). In Figure 2, we can also
observe the typical recordings of MAP during resting state
in all studied groups. Note that BP variability is significantly
TABLE 1 | Haemodynamic measurements.
Parameters Groups
Sham (7) SAD (7) CKD (7) SAD+CKD (6)
MAP (mmHg) 107± 1 109±1 154± 3ab 182±7abc
DAP (mmHg) 80± 2 83±3 128± 10ab 145±10abc
SAP (mmHg) 140± 2 135±3 184± 10ab 224±10abc
HR (bpm) 344± 5 366±6 356± 8 387±16a
SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, mean arterial
pressure; HR, heart rate. All values are expressed as means ± SEMs. The number in
parentheses represents the number of animals in each group. ap < 0.05 vs. Sham; bp <
0.05 vs. SAD; cp < 0.05 vs. CKD.
increased in the SAD+CKD animals when compared to all other
groups.
Renal Function Evaluation
We also evaluated the effects of BPV on renal function
parameters, including GFR, RPF, RBF and RVR (Figure 3).
Inulin clearance results (Figure 3A) demonstrated that GFR
was not modified by SAD (Sham: 6.5 ± 0.4 vs. SAD:
6.6 ± 0.4mL/min/Kg). As expected, CKD rats presented a
pronounced reduction in GFR (1.8 ± 0.2 mL/min/Kg, p <
0.01), which was not worsened by the combination with
SAD (1.9 ± 0.4mL/min/Kg, p < 0.01). RPF (Figure 3B),
determined using PAH clearance, was decreased in SAD rats
(23.7 ± 1.4mL/min/Kg, p < 0.05) when compared to sham
animals (27.9 ± 2.3 mL/min/Kg). Once again, PAH clearance
was reduced in CKD rats (4.5 ± 0.3mL/min/Kg, p < 0.01);
however, SAD+CKD group presented a further reduction in
RPF (2.9 ± 0.2mL/min/Kg, p < 0.01). To calculate the RBF,
we also quantified the haematocrit. SAD rats presented normal
haematocrit (39 ± 2%) when compared to sham group (43 ±
2%). CKD animals demonstrated a decrease in this parameter (29
± 1%, p < 0.01), which was not worsened by SAD (32± 1%, p <
0.01). The RBF analysis (Figure 3C) followed the same pattern as
the RPF results. SAD resulted in reduced RBF (Sham: 53.3 ± 4.0
vs. SAD: 41.4± 2.5mL/min/Kg, p < 0.05). CKD group displayed
a marked decline in RBF (6.4± 0.4mL/min/Kg, p < 0.01), which
was worsened by combination with SAD (3.5 ± 0.7mL/min/Kg,
p < 0.01). As expected, based on the renal blood flow results,
RVR (Figure 3D) was slightly increased in SAD rats (2.8 ± 0.2
a.u., p < 0.05) compared to sham animals (2.1 ± 0.1 a.u.). CKD
group presented an enhanced RVR (22.4 ± 2.7 a.u., p < 0.01),
with a further increase in SAD+CKD animals (32.2 ± 1.8 a.u.,
p < 0.01). Urinary water excretion was augmented in SAD (25.2
± 0.7 mL/24 h, p < 0.05) group when compared to sham (12.5
± 1.3mL/24 h) animals. Experimental induction of CKD led to
a further increase on urine excretion (38.3 ± 3.2mL/24 h, p <
0.01), which was much more prominent in SAD+CKD (57.4 ±
6.0 mL/24 h, p < 0.01) group.
Corroborating the inulin and PAH clearance results, the
plasma urea levels are demonstrated in Figure 4. Sinoaortic
denervation did not change uraemia (5.9 ± 0.4mmol/L)
compared to the sham group (6.4 ± 0.3mmol/L). As expected,
CKD animals presented hyperuraemia (15.5 ± 1.3mmol/L,
p < 0.01), which was aggravated in the SAD+CKD group (22.1
± 2.5mmol/L, p < 0.01).
Although SAD did not modify inulin clearance, the
correlation analysis between BPV and GFR demonstrated a
negative relationship between these parameters in the SAD
(r = −0.79, p < 0.05), CKD (r = −0.99, p < 0.05) and
SAD+CKD (r =−0.81, p < 0.05) groups (Figure 5).
Quantification of Superoxide Production
Superoxide production was assessed using flow cytometry with
DHE (median of fluorescence intensity). As illustrated in
Figure 6, SAD caused an increase in ROS generation (2757 ±
374, p < 0.01) when compared to the sham group (1045 ± 52).
CKD also resulted in augmented superoxide production (1830±
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FIGURE 1 | Typical recordings of phenylephrine-induced bradycardic responses (A) and sodium nitroprusside-induced tachycardic responses (B) and
quantification of baroreflex sensitivity index (BSI) (A,B) in all studied groups. The graphs show that both SAD and CKD decrease the BSI. However, this
condition is aggravated when these two situations are concomitant. Values are means ± SEMs. All groups have n = 5. ap < 0.05 vs. Sham group; bp < 0.05 vs. SAD
group; cp < 0.05 vs. CKD group. Two-way ANOVA.
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FIGURE 2 | Blood pressure variability (BPV) determined through the
standard deviation of mean arterial pressure (MAP). (A) Typical
recordings showing the arterial pressure measurements at resting conditions.
The black tracing represents pulsatile pressure and the gray line represents
MAP. Note that BPV is remarkably enhanced when SAD and CKD are
concomitant. (B) Bar graph showing the quantification of the SD of MAP in all
studied groups. Once again, both SAD and CKD resulted in augmented BPV,
and the association of these conditions caused an even more pronounced
increase in BPV. Sham and SAD n = 4, CKD and SAD+CKD n = 5. Values are
means ± SEMs. ap < 0.05 vs. Sham group; bp < 0.05 vs. SAD group; cp <
0.05 vs. CKD group. Two-way ANOVA.
66, p < 0.01), which was worsened in the SAD+CKD animals
(4468± 529, p < 0.01).
Cardiac and Kidney Hypertrophy and
Glomerular Collagen Deposition
Table 2 presents the results of cardiac and kidney hypertrophy.
SAD and CKD groups showed an increased heart weight/body
weight ratio when compared to sham group. The cardiac
hypertrophy was worsened in SAD+CKD group. The kidney
weight/body weight ratio was elevated only in SAD+CKD
animals.
Figure 7 demonstrates the collagen deposition in the
glomerulus determined by Masson’s Trichrome staining.
Typical photomicrographs of all studied groups are displayed
in Figure 7A, showing that, as expected, CKD resulted in
glomerulosclerosis; however, collagen deposition was further
increased when SAD and CKD occurred together. The
quantification of the percentage glomerular area stained
with Masson’s Trichrome (Figure 7B) demonstrates that SAD
did not alter glomerular collagen deposition (sham: 9.3 ±
1.5, SAD: 11.0 ± 0.8%). On the other hand, CKD resulted
in glomerulosclerosis (44.8 ± 1.2%, p < 0.01), which was
exacerbated in the SAD+CKD group (49.9 ± 1.2%, p < 0.01).
The glomerulosclerosis score also confirmed these results. No
differences were observed between the sham (1 ± 0) and SAD (1
± 0) groups. CKD increased the glomerulosclerosis index (2.2
± 0.07, p < 0.01) and the occurrence of SAD and CKD together
worsened this parameter (2.5± 0.07, p < 0.01).
DISCUSSION
In the past few years, several studies have demonstrated that a
variety of diseases, such as atherosclerosis, diabetes and CKD,
share a common factor: increased BPV (Roman et al., 2001; Di
Iorio et al., 2012; Ushigome et al., 2014). In this scenario, BPV
quantification emerges as a possible new marker of target-organ
damage. Data from clinical studies demonstrated a significant
association between BPV and cardiovascular mortality risk and
renal death (Di Iorio et al., 2015). BPV is also correlated with
a worse prognosis in cardiovascular and renal diseases (Parati
et al., 2012; Di Iorio et al., 2013). However, both experimental
and clinical studies have focused in evaluating BPV after the
onset of the disease, and it is likely the observed dysfunction
may have occurred due to other factors besides increased BPV. In
the present study we developed an experimental design that was
able to induce increased BPV prior to the onset of kidney disease
and our results show that SAD prior to CKD induction worsens
renal function, with diminished RBF, increased RVR, as well as
augmented uraemia and glomerulosclerosis. Taken together, our
results showed that increased BPVmay accelerate the progression
of CKD, indicating that BPV seems to be an important risk factor
to the progression of kidney injury and it should be taken in
consideration in the clinical practice.
Although SAD was initially considered a neurogenic
hypertension model (Krieger, 1964), it can be considered an
excellent experimental model to study the effects of augmented
BPV, since the removal of the baroreflex afferent pathway, leads
to a diminished BSI and increased BPV with no long-term
changes in blood pressure (Su and Miao, 2002). The induction
of CKD through 5/6 nephrectomy also resulted in a reduction
of BSI and augmented BPV. Similar to our data, Griffin et al.
(2004) demonstrated an increased BPV in nephrectomised
rats. Clinical studies also showed an augmented BPV and
diminished BSI in patients with chronic renal failure (Tozawa
et al., 1999; Studinger et al., 2006; Di Iorio et al., 2012). Although
CKD animals presented higher values of blood pressure but
lower BSI than SAD group, we cannot rule out the effects on
hypertension per se on BSI. It is well-established in the literature
that increased values of blood pressure decrease baroreflex
sensitivity in different experimental hypertension models
(Vasquez et al., 1994; Peotta et al., 2007; Klippel et al., 2016)
and when comparing sham to CKD animals as well as SAD to
SAD+CKD group, it appears that increased blood pressure may
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FIGURE 3 | Renal function evaluation. (A) Glomerular filtration rate (GFR) determined through inulin clearance. As expected, CKD resulted in a marked reduction in
GFR, which was not aggravated by its association with SAD. (B) Renal plasma flow (RPF) determined using PAH clearance. Both the SAD and CKD groups presented
a reduced RPF, which was more pronounced in CKD animals. The association of SAD and CKD exacerbated this condition. (C) Renal blood flow (RBF) in all studied
groups. Once again, SAD and CKD animals also presented reduced RBF; this reduction was greater in animals that underwent 5/6 nephrectomy. The association of
SAD and CKD worsened this parameter. (D) Renal vascular resistance (RVR) in all studied groups. In accordance with the previous results, RVR was augmented in
SAD and CKD animals; this increase was more pronounced in the CKD group. When SAD and CKD coexist, the rise in RVR is exacerbated. Sham n = 8, SAD n =
10, CKD and SAD+CKD n = 5. Values are means ± SEMs. ap < 0.01 vs. Sham group; bp < 0.01 vs. SAD group; cp < 0.01 vs. CKD group. Two-way ANOVA.
Two-way ANOVA, Student’s t-test.
have contributed to decrease BSI. Another factor that should
be considered is the effects of cardiac hypertrophy on BSI.
Studies have demonstrated that increased cardiac mass, without
hypertension, leads to an impairment of baroreflex function in
different animal models (Meyrelles et al., 1998; Gava et al., 2004).
In agreement with this, in experimental models of hypertension,
the development of baroreflex dysfunction coincides with
the onset of cardiac hypertrophy (Head, 1994). In our study,
both SAD and CKD groups present cardiac hypertrophy and
reduced BSI, and these alterations were further increased in
SAD+CKD animals, indicating that, besides the aforementioned
factors, cardiac hypertrophy may have contributed to decreased
baroreflex sensitivity.
One of the most important findings of our study concerns
the association of SAD and CKD. In almost all analyzed
parameters, when SAD and CKD were concomitant, the animals
displayed worsened function. Occurring together, SAD and
CKD resulted in a two-fold higher reduction in BSI and a
1.5-fold higher increase in BPV. The mechanisms involved in
these alterations are not fully understood; however, studies have
noted changes in sympathetic activity. According to Irigoyen
et al. (1995), chronic SAD rats present several short periods
of sympathetic hyperactivity, which could contribute to blood
pressure fluctuations. Spectral analysis of the arterial pressure
FIGURE 4 | Plasma values of urea (mmol/L). Sinoaortic denervation did not
modify uraemia. As expected, CKD animals presented hyperuraemia, which
was more pronounced in the SAD+CKD group. Sham and SAD n = 4, CKD
n = 7, SAD+CKD n = 8. Values are means ± SEMs. ap < 0.05 vs. Sham
group; bp < 0.05 vs. SAD group; cp < 0.05 vs. CKD group. Two-way ANOVA.
demonstrated a rise in the low frequency component in both
mice (Fazan et al., 2005) and rats (Mostarda et al., 2010)
subjected to SAD, indicating an increase in the sympathetic
activity. Comparable to these data, Shan et al. (2004) showed that
rats with SAD presented higher levels of noradrenaline in areas
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FIGURE 5 | Scatterplot linear regression and correlation analysis between glomerular filtration rate (GFR) and blood pressure variability (BPV). Data
show a negative relationship of GFR and BPV in SAD, CKD and SAD+CKD group, but not in sham group. Sham and SAD n = 6, CKD n = 4, and SAD+CKD n = 5.
The correlation between variables was determined using Pearson’s correlation coefficient and a linear regression model.
FIGURE 6 | Quantification of reactive oxygen species (ROS) formation
through DHE fluorescence. Both SAD and CKD resulted in increased ROS
generation, and this condition was aggravated when SAD and CKD were
associated Sham and SAD n = 6, CKD and SAD+CKD n = 5. Values are
means ± SEM. ap < 0.05 vs. Sham group; bp < 0.05 vs. SAD group; cp <
0.05 vs. CKD group. Two-way ANOVA.
involved in the vasomotor control, such as medulla oblongata
and hypothalamus. The increase in sympathetic activity may also
be involved in augmented BPV in the CKD animals because
5/6 nephrectomy also results in an elevation of circulating
TABLE 2 | Body weight, cardiac, and kidney hypertrophy.
Parameters Groups
Sham (6) SAD (5) CKD (9) SAD+CKD (6)
Body Weight (g) 420± 8 373± 18a 358± 10a 296± 18abc
CW/BW (mg/g) 3.11± 0.14 3.81± 0.10a 3.70± 0.14a 5.29± 0.19abc
KW/BW (mg/g) 3.91± 0.10 4.32± 0.24 4.44± 0.22a 6.80± 0.47abc
CW/BW, cardiac weight to body weight ratio; KW/BW, kidney weight to body weight ratio.
All values are expressed as means ± SEMs. The number in parentheses represents the
number of animals in each group. ap < 0.05 vs. Sham; bp < 0.05 vs. SAD; cp < 0.05 vs.
CKD.
catecholamines (Amann et al., 2000; Leineweber et al., 2002).
The kidneys present both afferent and efferent sympathetic
fibers, and in addition to being the target of sympathetic
activity, they may also play a role as the source sympathetic
activity (Campese, 2000), including during chronic renal failure.
Corroborating this idea, Bigazzi et al. (1994) demonstrated
that 5/6 nephrectomised rats present augmented turnover of
noradrenaline in the posterior hypothalamic nucleus, which
was attenuated after bilateral rhizotomy. Therefore, because
sympathetic nervous system hyperactivity is a common feature
of both SAD and CKD, the combination of both interventions
may lead to even higher sympathetic activation, explaining the
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FIGURE 7 | Glomerular collagen deposition determined using Masson’s Trichrome (MT) staining. (A) Photomicrographs showing collagen deposition (blue)
in the glomerulus. Note that glomerulosclerosis is remarkably increased in the SAD+CKD group. (B) Percentage area of the glomerulus stained with MT. CKD led to
increased collagen deposition, which was more pronounced in the SAD+CKD group (C) Glomerulosclerosis score. As expected, CKD animals presented a greater
glomerulosclerosis index compared to the sham and SAD groups. The association of SAD+CKD worsened this parameter. The scale bar represents 25µm. Sham
and SAD n = 4, CKD and SAD+CKD n = 5. Values are means ± SEMs. ap < 0.05 vs. Sham group; bp < 0.05 vs. SAD group; cp < 0.05 vs. CKD group. Two-way
ANOVA.
reduction in BSI and elevation in BPV found to be more
prominent in the SAD+CKD group.
Regarding the haemodynamic parameters, the SAD animals
did not demonstrate any changes in arterial pressure nor heart
rate. This result is in accordance with the literature because
the SAD animals show hypertension only in the initial phase
of SAD. In the chronic phase, arterial pressure returns to
normal levels, although BPV remains high (Norman et al., 1981).
Nephrectomised animals also presented hypertension, which was
also an expected result because studies have demonstrated that
the infarction of the renal poles results in an elevation of arterial
pressure (Griffin et al., 2004). However, the resting values of
systolic, diastolic, and MAP, as well as heart rate, were more
elevated in the SAD+CKD group. The hyperactivation of the
sympathetic nervous system by the combination of SAD and
CKDmay play a role in the development of these higher levels of
hypertension, although we cannot rule out the role of the renin
angiotensin system (RAS). Nephrectomised animals present an
elevation of plasma (2 weeks after nephrectomy) and tecidual
angiotensin II (Mackie et al., 2001; Vaziri et al., 2007). Nishimura
et al. (2007) demonstrated that renin, angiotensin-converting
enzyme (ACE) and AT1 receptor mRNA expression is elevated in
the hypothalamus and brainstem of nephrectomised animals. It is
interesting to note that these regions are involved in sympathetic
activation, and the increase of tecidual RAS in these areas may
play a role in the sympathetic hyperactivity observed in CKD.
SAD also leads to an increase in the RAS system. Angiotensin
II levels, AT1 receptors mRNA expression and ACE activity
are elevated in the heart, aorta and kidney of SAD animals
(Miao et al., 2003; Shan et al., 2004; Feng et al., 2011). Because
both SAD and CKD result in augmented RAS, once again,
the combination of both conditions may be additive and lead
to higher levels of hypertension in the SAD+CKD group. In
addition, activation of tecidual RAS may also be involved in the
cardiac hypertrophy presented in the SAD and the CKD animals.
The increase in cardiac weight/body weight ratio was even higher
in the SAD+CKD group, and the mechanisms involved in this
alteration may include activation of SNS, augmented tecidual
RAS and the higher level of hypertension presented by the
animals.
In the renal function studies, we observed that SAD per se
did not produce any changes in the GFR. As expected, CKD
animals presented a remarkable reduction in the GFR, and the
combination of SAD and CKD did not worse this parameter.
However, in the SAD+CKD group, the reduction of renal plasma
(RPF) and blood (RBF) flow and the increase in RVR were
statistically greater than in all other groups.
The maintenance of the GFR in the SAD+CKD group
compared to CKD animals, even with a smaller RBF, may involve
the RAS system. It is well-established that angiotensin II is
able to cause a preferential constriction of the efferent arteriole,
increasing glomerular hydrostatic pressure and maintaining the
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GFR (Bidani et al., 2013). As both SAD and CKD increase
intrarenal angiotensin II (Shan et al., 2004; Vaziri et al., 2007),
we can speculate that a greater activation of RAS in SAD+CKD
may prevent a greater reduction of GFR in this group. Although
SAD+CKD animals did not present a further reduction in
GFR, it seems that the combination of both procedures
resulted in a worsened renal function, because other analyzed
parameters such as hyperuraemia and glomerulosclerosis were
exacerbated in this group. Additionally, the correlation analysis
showed that there is a negative relationship between GFR
and BPV.
Another pathway that might be involved in the observed
changes in renal function is the increased sympathetic nerve
activity. Even thought we did not quantify renal sympathetic
nerve activity in the present investigation, studies have
demonstrated that both SAD and CKD result in increased
sympathetic drive (Irigoyen et al., 1995; Amann et al., 2000;
Leineweber et al., 2002; Fazan et al., 2005). It is well-stablished
that SNS activity plays an important role in the genesis
of hypertension; however, the deleterious effects of increased
sympathetic drive on the kidneys are not only caused by higher
blood pressure levels (Joles and Koomans, 2004). Prolonged SNS
hyperactivity can damage intrarenal blood vessels by inducing
proliferation of smooth muscle cells and fibroblasts in the vessel
wall (Zhang and Faber, 2001; Erami et al., 2002). In addition,
activation of renal sympathetic fibers result in vasoconstriction
and reduce RBF (Johns et al., 2011), leading to renal injury.
In our study, it is possible that the combination of SAD and
CKD resulted in an even higher sympathetic drive than when
these situations occurred alone, contributing to a worsened renal
function on SAD+CKD group.
Although we speculate that increased BPV in SAD+CKD
may be responsible for the observed changes in renal function,
we cannot rule out the role of hypertension, since this group
presented higher levels of systolic, diastolic and MAP. However,
the effects of elevated BPV in renal organ damage may be
more important than the classic risk factors of a high blood
pressure. Corroborating this idea, Miao et al. (2006) identified
that increased short-term BPV is a more critical determinant
for renal damage than mean BP levels. An important clinical
study developed by Parati et al. (1987) demonstrated that, for
nearly any level of blood pressure, the patients who presented
higher BPV also had increased prevalence and severity of organ
damage, in both short and long term evaluation of BPV. Cross-
sectional studies in non-treated hypertensive patients have found
an increased short term BPV to be positively correlated with
impaired renal function (Parati et al., 2012). Taken together, these
data indicate that, regardless the blood pressure levels, there is
a relationship between BPV and the severity of organ damage,
including in hypertensive states.
The alterations in renal haemodynamic observed in our
study may occur also due to changes in the nitric oxide
(NO) system, which plays an important role in regulating
RBF (Mattson and Meister, 2005; Toda and Okamura, 2011),
especially counterbalancing the effects of increased sympathetic
activity. When SNS activity is augmented, NO formation also
increases to prevent kidney ischaemia, mainly in medullar levels
(Zou and Cowley, 2000). However, a higher NO generation does
not necessarily leads to more effects of this molecule, especially
if oxidative stress is increased, as observed in the SAD+CKD
group. Similar to these data, studies have demonstrated that both
experimental SAD and CKD induce a smaller NO bioavailability
(Nakayama et al., 2009; Wu et al., 2013). Our data shows that
SAD+CKD animals present higher oxidative stress in the blood,
indicating that renal oxidative could also be increased. Therefore,
the greater increase in RVR and, consequently, the reduction
in RBF, may be attributed to the augmented oxidative stress
observed in the SAD+CKD group, reducing NO bioavailability.
Thus, the prominent effects of the association of SAD and
CKD on RBF and RVR may be attributed to activation of
renal vasoconstrictive systems (SNS and SRA) and reduced NO
bioavailability.
The reduction of NO bioavailability may also have played a
role in the enhanced levels of glomerulosclerosis presented by the
SAD+CKD rats. Corroborating this hypothesis, previous studies
have demonstrated that eNOS −/− mice exhibit exacerbated
renal interstitial injury and global glomerulosclerosis (Nakayama
et al., 2009) and that iNOS −/− mice show higher levels
of tubular apoptosis (Miyajima et al., 2001) and interstitial
fibrosis (Hochberg et al., 2000). In the kidney, NO reduced
mesangial proliferation and extracellular matrix synthesis (Zhou
et al., 2004) and the mechanisms involved in these effects
include inhibition of TGF-β1 and its downstream effector
molecule fibronectin (Zhou et al., 2008), inhibition of TNF-
α (Whiting et al., 2013) and modulation of cytokine-induced
metalloproteinases and inhibitors of metalloproteinases (Yang
et al., 2008).
Taken together, these data indicate that increased BPV
prior to renal dysfunction induced by SAD, as well as
hypertension, exacerbates renal injury, and glomerulosclerosis in
an experimental model of CKD. These results reinforce the role
of increased BPV and hypertension as important markers to the
progression of renal diseases.
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